Skip to main content
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRS ISIN · US00461U1051 LEI · 5493000B2LQ9QTW1DF52 US Manufacturing
Filings indexed 844 across all filing types
Latest filing 2023-02-17 Director's Dealing
Country US United States of America
Listing US ACRS

About Aclaris Therapeutics, Inc.

https://www.aclaristx.com/

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel drug candidates for immuno-inflammatory diseases. The company leverages its core expertise in drug discovery, development, and kinase inhibition to create a pipeline of both small and large molecule drugs. Aclaris focuses on translating scientific discovery into innovative therapies to address the needs of patients with underserved conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-02-17 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-14 English
AMENDMENT NO. 1 TO THE SCHEDULE 13G
Major Shareholding Notification
2023-02-14 English
SC 13G/A
Major Shareholding Notification
2023-02-13 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-10 English
SEC SCHEDULE 13G
Major Shareholding Notification
2023-02-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.